Apigenin is a naturally occurring flavonoid concentrated in chamomile, parsley, and celery that has attracted attention for its calming, antioxidant, and other biological properties. Before adding a high-dose apigenin supplement to your routine, however, there is a pharmacology question worth understanding: apigenin interacts with the cytochrome P450 (CYP450) enzyme system, the liver’s primary machinery for breaking down most prescription and over-the-counter drugs.
When a flavonoid like apigenin inhibits a CYP enzyme, the drugs that depend on that enzyme for clearance can accumulate to higher-than-expected blood concentrations. The three enzymes most relevant to apigenin are CYP1A2, CYP2C9, and CYP3A4. Together these enzymes handle a substantial share of commonly prescribed medications. This article explains the mechanisms, summarizes the available evidence, and identifies who should exercise the most caution. These statements have not been evaluated by the FDA; this is informational, not medical advice.
Key Takeaways
- Apigenin inhibits CYP1A2, CYP2C9, and CYP3A4 in vitro — the three liver enzymes responsible for clearing a large portion of commonly prescribed drugs.
- The highest-risk drug categories are warfarin (CYP2C9-dependent), CYP3A4-dependent statins such as simvastatin and lovastatin, and benzodiazepines such as midazolam and alprazolam.
- Most supporting evidence is from in vitro studies; human clinical pharmacokinetic data on apigenin-drug interactions is limited, so real-world magnitude of effect remains uncertain.
- Stacking apigenin with other sedatives — including melatonin, benzodiazepines, and alcohol — may compound CNS depression and warrants caution.
- Dietary apigenin from chamomile tea or parsley is unlikely to reach pharmacologically inhibitory concentrations; the concern is primarily relevant to high-dose concentrated supplement forms.
CYP450 Enzymes: The Liver's Drug-Processing System
Cytochrome P450 enzymes are a superfamily of proteins concentrated primarily in the liver and small intestine. Their core function is oxidative metabolism — converting lipophilic compounds, including drugs, plant molecules, and hormones, into more water-soluble metabolites the kidneys can excrete. Block one of these enzymes and you slow the clearance of every drug substrate that depends on it.
The clinical importance of CYP inhibition is well recognized in pharmacology. When a second compound — whether a prescription drug, a food component, or a botanical supplement — occupies or blocks a CYP enzyme, the affected drug’s half-life can lengthen and plasma concentration can rise above the intended therapeutic range, increasing adverse-effect risk without any change in dose. Herb-drug interactions operating through this metabolic mechanism are an active area of research, and the CYP system is consistently identified as the primary route by which botanical compounds alter drug pharmacokinetics [6].
Apigenin and CYP1A2
CYP1A2 is one of the major hepatic enzymes and is responsible for metabolizing caffeine, theophylline, clozapine, olanzapine, and several antidepressants and cardiovascular agents. Early in vitro work on dietary flavonoids demonstrated that structurally related compounds can both serve as substrates for and inhibitors of multiple CYP isoforms, including CYP1A2 [1]. Because apigenin is a flavone with hydroxyl groups at the 4′, 5, and 7 positions, it shares the scaffold features associated with CYP binding in this compound class.
More targeted research has examined how human family 1 CYP enzymes — CYP1A1, CYP1A2, and CYP1B1 — directly oxidize apigenin [5]. This substrate-enzyme relationship is relevant because when apigenin occupies the active site of CYP1A2 it can slow the metabolism of coadministered CYP1A2-dependent drugs through competitive inhibition. Separately, apigenin has been shown to inhibit the CYP monoxygenase branch of the arachidonic acid cascade [2], indicating that its CYP-related effects extend across more than one enzymatic context.
Apigenin and CYP2C9: The Warfarin Concern
CYP2C9 is the primary enzyme responsible for metabolizing S-warfarin, the more pharmacologically active enantiomer of the widely used anticoagulant. It also clears a range of NSAIDs including ibuprofen and celecoxib, several oral hypoglycemics such as glipizide and tolbutamide, and the antihypertensive losartan. In vitro studies of dietary flavonoids have consistently found inhibitory activity against CYP2C9 across multiple members of this compound class [1].
The structural features of flavonoids that determine CYP2C9 inhibitory potency — particularly the degree of hydroxylation and methylation on the flavone ring — have been explored in intestinal epithelial cell models [4]. Apigenin’s three free hydroxyl groups influence its binding affinity to CYP active sites. For anyone on warfarin, even a modest CYP2C9 inhibitor is clinically significant: slowed S-warfarin clearance can extend prothrombin time and raise bleeding risk without any visible change in dose or symptom.
Apigenin and CYP3A4: The Broadest Interaction Risk
CYP3A4 is the most widely implicated drug-metabolizing enzyme, responsible for clearing an estimated 30–50 percent of all pharmaceuticals. Its substrate list includes simvastatin, lovastatin, midazolam, alprazolam, triazolam, cyclosporine, tacrolimus, and many others. Research specifically examining structurally diverse flavonoids found that multiple compounds in this chemical class inhibit CYP3A4, with binding affinity varying by substituent pattern on the core flavone scaffold [3].
Because of CYP3A4’s extraordinarily broad substrate profile, inhibition here carries the widest practical implications. For individuals combining an apigenin supplement with a prescribed benzodiazepine — for example, taking a chamomile-derived supplement alongside alprazolam for anxiety — there is a theoretical risk of enhanced and prolonged sedation. For those on certain statins whose clearance is CYP3A4-dependent, elevated drug exposure raises the risk of myopathy. The CYP3A4 concern also intersects with apigenin’s direct activity at GABA-A benzodiazepine receptor sites: stacking mechanisms that separately enhance sedation is worth discussing with a clinician.
Drug Categories That Warrant the Most Caution
Three categories stand out based on their CYP enzyme dependencies and narrow therapeutic windows. First, anticoagulants: warfarin’s reliance on CYP2C9 for S-enantiomer clearance means any CYP2C9 inhibitor can unpredictably raise INR. Second, CYP3A4-dependent statins: lovastatin and simvastatin are highly dependent on CYP3A4 for first-pass and systemic clearance; accumulation is associated with myopathy and, in severe cases, rhabdomyolysis. Pravastatin and rosuvastatin, which are less CYP3A4-reliant, carry lower theoretical interaction risk. Third, benzodiazepines and related sedative-hypnotics: midazolam, triazolam, and alprazolam are well-established CYP3A4 substrates, and concurrent sedatives — including melatonin and alcohol — could compound CNS depression through additive mechanisms.
Herb-drug interaction research consistently identifies metabolic enzyme inhibition as the predominant mechanistic route through which botanical supplements alter conventional drug pharmacokinetics [6]. This concern is not unique to apigenin across the flavonoid class, but apigenin’s growing availability as a standalone supplement at doses far exceeding typical dietary exposure — commercial products range from 50 mg to 450 mg per serving — makes the interaction risk more concrete than it would be from trace amounts consumed through food.
Interpreting the Evidence: In Vitro Limits and Real-World Relevance
Virtually all of the data supporting apigenin’s CYP-inhibitory profile comes from in vitro studies — experiments in cell-free enzyme preparations or cell lines rather than in living humans. Concentrations used in vitro sometimes exceed what is achievable through food or even supplementation. However, the gap between in vitro inhibitory concentrations and realistic high-dose supplement exposure is considerably smaller than it was when only dietary flavonoid intake was being considered.
Molecular modeling and docking studies have further characterized the structural basis of CYP3A4 flavonoid binding [3], and cell-based work has clarified how hydroxylation pattern modulates inhibitory activity [4]. Multiple independent research efforts examining flavonoids across different enzyme isoforms have arrived at consistent inhibitory signals for CYP1A2 [1] [5] [2], CYP2C9 [1], and CYP3A4 [3]. What remains limited is well-powered human pharmacokinetic data with apigenin specifically. Until such data exist, the in vitro signal provides the primary rational basis for precaution, and that signal is reproducible across multiple laboratories and methodologies.
🛒 Where to Buy Apigenin
- Momentous Momentous ApigeninLab-tested / studied
capsules, 50 mg per capsule — Andrew Huberman’s publicly recommended brand; NSF Certified for Sport; single-ingredient, no fillers - Double Wood Supplements Apigenin 50mg
capsules, 50 mg per capsule, 120 count — High-volume value pick; third-party tested for purity; frequently top-ranked on Amazon - Nutricost Apigenin 50mg
capsules, 50 mg per capsule, 120 count — FDA-registered facility; gluten-free, non-GMO; competitive price-per-dose - Swanson Apigenin 50mg
capsules, 50 mg per capsule, 90 count — Established supplement brand; GMP-certified manufacturing; widely available, low cost
As an Amazon Associate we earn from qualifying purchases. Shilajit quality varies widely — always choose a product with a published third-party heavy-metal test (COA) before buying.
A Note on the Evidence
The evidence for apigenin’s CYP inhibitory effects comes predominantly from in vitro studies, and robust human clinical pharmacokinetic data are lacking; real-world effect sizes remain uncertain. Individuals taking warfarin, benzodiazepines, CYP3A4-dependent statins, narrow-therapeutic-window antiepileptics, or other medications cleared by CYP1A2, CYP2C9, or CYP3A4 should consult a qualified healthcare provider before starting or stopping apigenin supplements. These statements have not been evaluated by the FDA; apigenin is not intended to diagnose, treat, cure, or prevent any disease.
Frequently Asked Questions
What is CYP enzyme inhibition and why does it matter for supplements?
CYP enzymes in the liver break down most drugs into metabolites the body can excrete. When a compound inhibits one of these enzymes, affected drugs clear more slowly and can accumulate to higher blood concentrations, raising both effect and adverse-event risk without any change in dose. Herb-drug interactions operating through CYP inhibition are a recognized pharmacological concern documented across botanical compounds [6].
Which CYP enzymes does apigenin specifically affect?
In vitro research demonstrates inhibitory activity at CYP1A2, CYP2C9, and CYP3A4. Studies examining dietary flavonoids broadly found consistent inhibitory signals across these isoforms [1], while apigenin-specific research has further characterized its interaction with CYP1A2 as both a substrate and inhibitor [5] and its inhibition of CYP monoxygenase pathways [2].
Why is warfarin particularly concerning with apigenin?
Warfarin’s S-enantiomer — the pharmacologically dominant form — is metabolized almost exclusively by CYP2C9. Apigenin’s inhibitory activity at CYP2C9, documented across dietary flavonoid research [1], could slow warfarin clearance and raise INR without any change in dose, increasing bleeding risk unpredictably. Anyone on anticoagulant therapy should not start apigenin supplements without medical guidance.
Are all statins equally at risk from CYP3A4 inhibition?
No. Statins differ substantially in their CYP3A4 dependence. Simvastatin and lovastatin rely heavily on CYP3A4 for first-pass and systemic clearance, so inhibition of that enzyme — which structurally diverse flavonoids including apigenin have been shown to produce in vitro [3] — could significantly raise their plasma concentrations. Pravastatin, rosuvastatin, and fluvastatin use other clearance routes and carry lower theoretical interaction risk.
Does eating chamomile or parsley create these drug interaction risks?
Probably not at typical dietary amounts. The concentrations required to inhibit CYP enzymes in vitro generally exceed what is achieved through normal food or tea consumption. The concern applies primarily to concentrated high-dose supplement forms where plasma apigenin levels may approach pharmacologically relevant ranges. This distinction between dietary and supplement-level exposure is important context when evaluating the in vitro literature.
Can I take apigenin with melatonin or alcohol safely?
This question involves two separate mechanisms. Apigenin’s partial agonist activity at GABA-A benzodiazepine receptor sites can promote sedation, and combining it with melatonin or alcohol — both of which also suppress CNS activity — carries an additive sedation risk independent of CYP interactions. Apigenin may additionally slow the clearance of compounds metabolized by the enzymes it inhibits. This is an area where consulting a pharmacist or physician is advisable rather than self-experimenting, particularly at supplement doses.
References
- Breinholt VM et al. In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2002). PMID 11955666
- Steuck M et al. Food Polyphenol Apigenin Inhibits the Cytochrome P450 Monoxygenase Branch of the Arachidonic Acid Cascade. Journal of agricultural and food chemistry (2016). PMID 27933871
- Mitrasinovic PM et al. On the inhibition of cytochrome P450 3A4 by structurally diversified flavonoids. Journal of biomolecular structure & dynamics (2022). PMID 34060409
- Karancsi Z et al. Effect of hydroxylated and methylated flavonoids on cytochrome P450 activity in porcine intestinal epithelial cells. Acta veterinaria Hungarica (2023). PMID 37141048
- Nagayoshi H et al. Oxidation of Naringenin, Apigenin, and Genistein by Human Family 1 Cytochrome P450 Enzymes and Comparison of Interaction of Apigenin with Human P450 1B1.1 and Scutellaria P450 82D.1. Chemical research in toxicology (2023). PMID 37783573
- Wang T et al. Herb-drug interaction potential of Astragali Radix: a metabolic perspective. Drug metabolism reviews (2025). PMID 39692050
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
